A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
GSK plc operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 43.1B | 43.1B | 40.1B | 37.9B | 36.1B | 46.9B |
| Net Income | 8.3B | 8.3B | 3.8B | 6.6B | 19.3B | 7.0B |
| EPS | $4.15 | $4.15 | $1.80 | $3.39 | $10.22 | $2.75 |
| Free Cash Flow | 8.4B | 8.4B | 6.6B | 6.8B | 7.7B | 10.9B |
| ROIC | 22.3% | 23.9% | 12.6% | 21.4% | - | 15.0% |
| Gross Margin | 72.4% | 72.4% | 71.2% | 71.8% | 67.4% | 66.0% |
| Debt/Equity | 1.11 | 1.11 | 1.30 | 1.41 | 2.08 | 1.13 |
| Dividends/Share | $1.69 | $1.69 | $1.49 | $1.43 | $2.27 | $2.16 |
| Operating Income | 10.5B | 10.5B | 5.1B | 8.4B | - | 8.5B |
| Operating Margin | 24.3% | 24.3% | 12.8% | 22.2% | - | 18.2% |
| ROE | 39.4% | 43.3% | 22.8% | 46.4% | 99.4% | 23.9% |
| Shares Outstanding | 2,002M | 2,002M | 2,096M | 1,956M | 1,885M | 2,550M |
GSK plc passes 4 of 9 quality checks, suggesting mixed fundamentals.
GSK plc trades at 31.4x trailing earnings, compared to its 15-year median P/E of 11.8x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 18.0x vs a median of 9.2x. The company's 5-year average ROIC is 18.2% with a gross margin of 69.7%. Total shareholder yield (dividends + buybacks) is 4.4%. At current prices, the estimated annualized return to fair value is -3.0%.
GSK plc (GSK) has a current P/E ratio of 31.4, compared to its historical median P/E of 11.8. The stock is currently considered Expensive based on its historical valuation range.
GSK plc (GSK) has a 5-year average return on invested capital (ROIC) of 18.2%. This indicates strong capital allocation and a potential competitive advantage.
GSK plc (GSK) has a market capitalization of $118.0B. It is classified as a large-cap stock.
Yes, GSK plc (GSK) pays a dividend with a trailing twelve-month yield of 2.87%. The company also returns capital through share buybacks, with a buyback yield of 1.54%.
Based on historical P/E analysis, GSK plc (GSK) appears expensive. The current P/E of 31.4 is 166% above its historical median of 11.8. The estimated fair value CAGR (P/E method) is 0.1%.
GSK plc (GSK) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
GSK plc (GSK) reported annual revenue of $43.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
GSK plc (GSK) has a net profit margin of 19.3%. This is a healthy margin.
GSK plc (GSK) generated $8.4 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
GSK plc (GSK) has a debt-to-equity ratio of 1.11. This indicates moderate leverage.
GSK plc (GSK) reported earnings per share (EPS) of $4.15 in its most recent fiscal year.
GSK plc (GSK) has a return on equity (ROE) of 43.3%. This indicates the company generates strong returns for shareholders.
GSK plc (GSK) has a 5-year average gross margin of 69.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 11 years of financial data for GSK plc (GSK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GSK plc (GSK) has a book value per share of $10.52, based on its most recent annual SEC filing.